Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,076,605
  • Shares Outstanding, K 115,764
  • Annual Sales, $ 59,610 K
  • Annual Income, $ -262,140 K
  • 60-Month Beta 1.17
  • Price/Sales 18.30
  • Price/Cash Flow N/A
  • Price/Book 4.84
Trade ARQT with:

Options Overview Details

View History
  • Implied Volatility 103.27% ( -14.05%)
  • Historical Volatility 76.47%
  • IV Percentile 37%
  • IV Rank 23.63%
  • IV High 339.03% on 10/19/23
  • IV Low 30.32% on 09/26/23
  • Put/Call Vol Ratio 0.09
  • Today's Volume 484
  • Volume Avg (30-Day) 1,354
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 29,631
  • Open Int (30-Day) 35,770

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.47
  • Low Estimate -0.50
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +57.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.99 +37.27%
on 06/10/24
9.85 -2.59%
on 06/26/24
+1.24 (+14.77%)
since 05/31/24
3-Month
6.99 +37.27%
on 06/10/24
13.17 -27.15%
on 04/09/24
-0.09 (-0.88%)
since 04/01/24
52-Week
1.76 +445.17%
on 12/01/23
13.17 -27.15%
on 04/09/24
+0.07 (+0.68%)
since 06/30/23

Most Recent Stories

More News
5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 41.72 (-0.41%)
VKTX : 55.87 (+5.40%)
LBPH : 31.06 (+14.91%)
ARQT : 9.67 (+3.98%)
RNA : 41.20 (+0.86%)
S&P Futures Higher After April CPI is Released

June S&P 500 E-Mini futures (ESM24) are trending up +0.45% this morning after April's CPI report was released.

ESM24 : 5,471.89s (-0.09%)
SMCI : 811.63 (-0.94%)
ORCL : 143.02 (+1.29%)
SCHW : 73.45 (-0.33%)
PARA : 10.15 (-2.31%)
CSCO : 47.47 (-0.08%)
GRAB : 3.51 (-1.13%)
MNDY : 239.90 (-0.36%)
EXPN.LN : 3,648.863 (-1.86%)
MRK.D.DX : 151.700 (-2.07%)
NESTE.H.DX : 16.945 (+2.45%)
ARQT : 9.67 (+3.98%)
S&P Futures Slip as Investors Cautiously Await U.S. Big Bank Earnings, U.S. Rates Stay in Focus

December S&P 500 futures (ESZ23) are trending down -0.24% this morning after three major U.S. benchmark indices closed lower on Thursday as hotter-than-expected U.S. inflation data bolstered bets on Federal...

ESZ23 : 4,694.27s (-0.58%)
DAL : 46.84 (-1.26%)
F : 12.78 (+1.91%)
BYND : 6.77 (+0.89%)
FAST : 62.40 (-0.70%)
JPM : 206.09 (+1.89%)
WFC : 60.49 (+1.85%)
C : 63.56 (+0.16%)
BLK : 779.73 (-0.96%)
PNC : 156.14 (+0.42%)
UNH : 493.56 (-3.08%)
DIM.FP : 146.700 (-4.31%)
Why Shares of Arcutis Biotherapeutics Fell This Week

The company released phase 3 trial results for an atopic dermatitis cream.

ARQT : 9.67 (+3.98%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 9.67 (+3.98%)
Why Shares of Arcutis Biotherapeutics Jumped This Week

The stock got a push when a British medical journal posted trials information on the company's lead product.

ARQT : 9.67 (+3.98%)
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

/PRNewswire/ -- MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched...

ARQT : 9.67 (+3.98%)
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

/PRNewswire/ -- LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing...

ARQT : 9.67 (+3.98%)
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...

ARQT : 9.67 (+3.98%)
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very...

ARQT : 9.67 (+3.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 10.17
2nd Resistance Point 9.88
1st Resistance Point 9.59
Last Price 9.63
1st Support Level 9.01
2nd Support Level 8.72
3rd Support Level 8.43

See More

52-Week High 13.17
Last Price 9.63
Fibonacci 61.8% 8.81
Fibonacci 50% 7.47
Fibonacci 38.2% 6.12
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar